Objective: The prevalence of and morbidity associated with treatment-resistant depression has motivated the exploration of treatment alternatives. In this study, quetiapine was compared with lithium in the augmentation of treatment-resistant depression.
Research Design And Methods: Open-label, comparative study in 20 patients with major depression who had failed to respond after 4 weeks of treatment with an antidepressant at the maximal recommended dose. Patients were randomised to either lithium or quetiapine in addition to the maximally dosed antidepressant and any other concurrent medications. Lithium was initiated at 600 mg/day; quetiapine was titrated to 400 mg by day 7.
Results: Depression, measured by the Hamilton Depression Rating Scale (HAM-D), significantly improved from baseline in both quetiapine (F(1,90) = 25.11, p < 0.0001) and lithium (F(1,90) = 34.54, p < 0.0001). The difference in improvement between the two groups began at day 14 and was seen at all timepoints thereafter (p < 0.05), with the quetiapine group showing greater improvement than the lithium group. In the Montgomery-Asberg Depression Rating Scale (MADRS) analysis, the difference between the quetiapine and lithium group was significant from day 28 onwards (p < 0.05), with subjects improving more in the quetiapine group than the lithium group. The treatment by week interaction showed a significant difference overall between the two groups (p < 0.0001). The severity of psychomotor retardation showed a significant decrease in the Widlocher Psychomotor Retardation Scale scores in the quetiapine (p < 0.0001) and lithium (p < 0.0001) groups.
Conclusions: In this pilot study, quetiapine was an effective augmenting agent in treatment-resistant depression.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1185/030079906X162809 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effect of repetitive and Deep Transcranial Magnetic Stimulation on quantitative electroencephalography in major depressive disorder.
Front Psychiatry
January 2025
Department of Psychiatry, Kemal Arıkan Psychiatry Clinic, Istanbul, Türkiye.
Background: F-8-coil repetitive transcranial magnetic stimulation (rTMS) and H-1-coil deep repetitive transcranial magnetic stimulation (dTMS) have been indicated for the treatment of major depressive disorder (MDD) in adult patients by applying different treatment protocols. Nevertheless, the evidence for long-term electrophysiological alterations in the cortex following prolonged TMS interventions, as assessed by quantitative electroencephalography (qEEG), remains insufficiently explored. This study aims to demonstrate the qEEG-based distinctions between rTMS and dTMS in the management of depression and to evaluate the potential correlation between the electrophysiological changes induced by these two distinct TMS interventions and the clinical improvement in depressive and anxiety symptoms.
View Article and Find Full Text PDFTrajectory of peripheral inflammation during index ECT in association with clinical outcomes in treatment-resistant depression.
Brain Behav Immun Health
February 2025
Department of Psychiatry & Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
Background: Electroconvulsive therapy (ECT) is a highly efficacious intervention for severe and intractable depression. Evidence suggests ECT provokes an initial acute inflammatory response that subsequently decreases with repeated administration. However, relationships between inflammatory changes and clinical effects are unclear.
View Article and Find Full Text PDFMicroRNA-3145 as a potential therapeutic target for hepatitis B virus: inhibition of viral replication via downregulation of HBS and HBX.
Front Microbiol
January 2025
Department of Microbiology, Faculty of Medicine, Shimane University, Izumo, Japan.
Current treatments for hepatitis B virus (HBV), such as interferons and nucleic acid analogs, have limitations due to side effects like depression and the development of drug-resistant mutants, highlighting the need for new therapeutic approaches. In this study, we identified microRNA-3145 (miR-3145) as a host-derived miRNA with antiviral activity that is upregulated in primary hepatocytes during HBV infection. The expression of its precursor, pri-miR-3145, increased in response to the the virus infection, and miR-3145 downregulated the hepatitis B virus S (HBS) antigen and hepatitis B virus X (HBX), thereby inhibiting viral replication.
View Article and Find Full Text PDFAutoimmune encephalitis: recovery, residual symptoms and predictors of long-term sequelae.
J Neurol Neurosurg Psychiatry
January 2025
Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
Background: Data regarding long-term recovery from autoimmune encephalitis (AE) remain limited.
Methods: This retrospective observational study investigated outcomes in 182 patients who met the 2016 criteria for definite AE. Recovery data were available in 172 patients.
Efficacy of Modified Electroconvulsive Therapy in Treatment-Resistant Schizophrenia.
Alpha Psychiatry
November 2024
Department of Psychiatry, Wuhan Wudong Hospital, Wuhan, China.
Objective: The aim of the study was to investigate the therapeutic effects of modified electroconvulsive therapy (MECT) in combination with risperidone tablets and psychotherapy in the treatment of patients with treatment-resistant schizophrenia (TRS).
Methods: Patients with TRS admitted to the psychiatric department of our hospital between January 2018 and December 2019 were selected as study participants. They were randomly divided into a control group and a study group, with the control group receiving risperidone tablets and psychotherapy, and the study group undergoing MECT as well as the control group treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!